-Down to Earth A high level UN panel on Access to Medicines wants members to make full use of TRIPS flexibilities to protect public health If ever India needed a clear endorsement of its laws on intellectual property rights (IPRs) and their application in meeting public health priorities, it has come from the highest quarters. The report of the UN Secretary General’s High Level Panel (HLP) on Access to Medicines has, directly...

-The Hindu While Monsanto and Indian seed companies spar, more worrying is the confused lawmaking underpinning regulation of patents Genetically Modified Organisms (GMOs) breed controversy like no other. Little wonder then that Monsanto’s much-maligned Bt cotton has spawned the mother of all intellectual property (IP) disputes in India, involving at least 15 different proceedings in various courts, government agencies and tribunals at last count. Most proceedings appear to have come at the behest...

-Frontline Medecins Sans Frontieres warns that the free or regional trade agreements that are being negotiated, which seek to strengthen current patent regimes, are a potential threat to the developing world’s access to life-saving drugs, which it sources mostly from India. WHEN NELSON MANDELA’S GOVERNMENT passed the Medicines and Related Substances Control Act in 1997 to make medicines more accessible to the poor, 39 big pharmaceutical companies filed law suits in...

-The Hindu Land should be given back if the project does not take off: SC New Delhi: Even as several prominent private builders have come under suspicion for delayed completion of housing projects, the Supreme Court has declared land a “scarce natural resource” and forbidden the government from using its powers of compulsory land acquisition to strip poor farmers of their livelihood only to transfer such land to private builders to feed...

-The Hindu The policy fails to acknowledge that IP is a market-driven model’ India’s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a “serious” hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts. The policy left the country’s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which...